We are live on
!
Find out more
ABG
Ally Bridge Group Portfolio holdings
AUM
$124M
1-Year Est. Return
249.88%
This Fund
S&P 500
This Quarter
Est. Return
+5.28%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$111M
AUM Growth
-$5.7M
(-4.9%)
Cap. Flow
+$5.19M
Cap. Flow
% of AUM
4.68%
Top 10 Holdings %
Top 10 Hldgs %
64.59%
Holding
34
New
4
Increased
10
Reduced
13
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$10.4M |
| 2 |
VRNA
Verona Pharma
VRNA
|
+$8.32M |
| 3 |
TECX
Tectonic Therapeutic
TECX
|
+$4.31M |
| 4 |
Praxis Precision Medicines
PRAX
|
+$3.16M |
| 5 |
Geron
GERN
|
+$2.39M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$12.3M |
| 2 |
ALMS
Alumis Inc
ALMS
|
+$3.5M |
| 3 |
Jasper Therapeutics
JSPR
|
+$2.62M |
| 4 |
EyePoint Inc
EYPT
|
+$2.59M |
| 5 |
ETNB
89bio
ETNB
|
+$2.49M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
ProMIS Neurosciences
PMN
$109M
| $1.03M | 0.93% |
59,388
-4,316
| -7% | -$91.6K |
|
27
Tyra Biosciences
TYRA
$1.82B
| $997K | 0.9% |
107,244
-67,819
| -39% | -$878K |
|
28
Context Therapeutics
CNTX
$56.4M
| $708K | 0.64% |
1,157,448
-419,314
| -27% | -$365K |
|
|
ETNB
29
DELISTED
89bio
ETNB
| – | – |
-317,833
| Closed | -$2.49M |
|
|
30
EyePoint Inc
EYPT
$1.02B
| – | – |
-348,000
| Closed | -$2.59M |
|
|
31
Jasper Therapeutics
JSPR
$22.9M
| – | – |
-122,424
| Closed | -$2.62M |
|
|
ALMS
32
Alumis Inc
ALMS
$3.57B
| – | – |
-445,259
| Closed | -$3.5M |
|
|
CLYM
33
Climb Bio
CLYM
$735M
| – | – |
-760,225
| Closed | -$1.37M |
|
|
ITCI
34
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-147,750
| Closed | -$12.3M |
|
Similar funds
MP
EWP
WFA
VWM
EI
TC
IFO
CRW
Ally Bridge Group's Q1 2025 Portfolio in Review
As of Q1 2025, Ally Bridge Group held 34 positions worth $111M, down 4.9% from $117M the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Ally Bridge Group deployed $5.19M of net new capital in Q1 2025, opening 4 new positions and adding to 10 existing holdings. Its largest new stake was Verona Pharma: 139,067 shares worth $8.83M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier.
On the sell side, the largest reduction was Xenon Pharmaceuticals, an estimated $2.27M trimmed.
- Ally Bridge Group's largest Q1 2025 buy was Verona Pharma: 139,067 shares worth $8.83M.
- Ally Bridge Group added most to SpringWorks Therapeutics in Q1 2025, an estimated $10.4M increase.
- Ally Bridge Group's biggest Q1 2025 reduction was Xenon Pharmaceuticals, cutting an estimated $2.27M.
- Ally Bridge Group fully exited Intra-Cellular Therapies Inc. in Q1 2025, selling an estimated $12.3M.
- Ally Bridge Group's ten largest holdings make up 65% of its $111M portfolio in Q1 2025.
- Ally Bridge Group opened 4 new positions and closed 6 in Q1 2025.
- Ally Bridge Group's portfolio value fell 4.9% quarter-over-quarter to $111M.
Based on Ally Bridge Group's 13F filing for Q1 2025, filed 15 May 2025.